Vietnam Drug Maker Develops New Cholera Vaccine
This article was originally published in PharmAsia News
Vietnam's Vaccine and Bio-Technology Products No. 1 says it has developed a cholera vaccine that is half again as effective as current drugs. The drug, being registered as mORACVAX, is expected to gain approval in time to treat a new outbreak of the disease. The director of Vietnam's National Institute of Hygiene and Epidemiology said the vaccine is 90 percent to 100 percent effective, compared with the 60 percent to 70 percent effectiveness of the current vaccine. The vaccine is expected to cost about $1.25 per dose, triple the cost of the current drug being administered. (Click here for more
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.